Good news from the German healthcare industry! Fresenius $FRE (-1,31 %) reported adjusted operating profit above market expectations in the fourth quarter. The strong performance of the Kabi and Helios segments contributed to this.
The results show that the company achieved an EBIT (earnings before interest and taxes) of 646 million euros (approx. USD 678 million), which is above the analysts' estimate of 634 million euros. This is a positive signal for investors and underlines the stability of the company.
For 2025, Fresenius expects organic sales growth of 4 % to 6 % before exceptional items and EBIT growth in constant currencies of between 3 % and 7 %. The company also plans to propose a dividend of EUR 1 per share for the 2024 financial year.
The results are also a good sign for the former dialysis division, Fresenius Medical Care, which also exceeded market expectations on Tuesday. An exciting year ahead! 👍